Goldman-backed drug maker Hepalink’s unit commits $40m to ORI Capital

Goldman-backed drug maker Hepalink’s unit commits $40m to ORI Capital

Photo: Getty Images Pro via DealStreetAsia

26 October, 2020

ORI Capital Shenzhen Hepalink Pharmaceutical Group

Printed by Unregistered user on Thu, 25 Dec 2025 23:31:38 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Shenzhen Hepalink invests $60m in TPG Biotechnology's latest fund

Venture Capital

Orchard Therapeutics raises $110m from Baillie Gifford, ORI Capital, Singapore's Temasek

Read more from Greater China

Global investors bet on Chinese AI as Wall Street fears bubble

Viewpoint: Hong Kong IPO market eyes continued recovery after comeback year 2025